Global non-small cell lung cancer market was valued at $18.4 billion in 2024 and is growing at a CAGR of 6.4% during the forecast period (2026-2035). Accelerated regulatory approvals for targeted therapies are significantly changing the NSCLC treatment landscape, offering quicker access to new oral treatments for patients with specific genetic mutations who have progressed after prior systemic therapies. This expedited access broadens treatment options in advanced disease stages and stimulates market growth; this regulatory momentum is increasingly reflected in recent approval decisions. For instance, in August 2025, the US FDA granted accelerated approval to Boehringer's HERNEXEOS (zongertinib tablets), the first orally administered targeted therapy for adults with HER2-mutant advanced non-small cell lung cancer (NSCLC) who have previously undergone systemic therapy. This approval, based on a 75% objective response rate from the Beamion-LUNG 1 clinical trial, follows Priority Review and Breakthrough Therapy Designation. The indication's continued approval may depend on further validation of clinical benefits in subsequent trials.
Browse the full report description of “Non-Small Cell Lung Cancer Market Size, Share & Trends Analysis Report by Type (Adenocarcinomas, Squamous Cell Carcinoma, Large Cell Carcinomas, and Others) by Therapy (Chemotherapy, Targeted Therapy, Radiation Therapy, Surgery, Cryosurgery, and Others) by Diagnosis (CT Scan, X-Rays, Sputum Cytology, Bronchoscopy, Laboratory Tests, Thoracoscopy, and Others), and by End-User Industry (Multispeciality Hospitals, and Cancer Research Centers) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/non-small-cell-lung-cancer-market
Leading Industry Players Advancing Innovation in the Non-Small Cell Lung Cancer Market
The key players in the non-small cell lung cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co., Inc., among others. These companies are driving innovation in digital health solutions such as telemedicine, electronic health records, remote patient monitoring, and AI-powered clinical tools, shaping the future of healthcare delivery globally.
- In November 2025, the FDA granted accelerated approval for sevabertinib (Hyrnuo), a kinase inhibitor, for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with HER2 (ERBB2) tyrosine kinase domain activating mutations after prior systemic therapy. Additionally, the Oncomine Dx Target Test has been approved as a companion diagnostic to detect these mutations in eligible NSCLC patients.
- In November 2025, the FDA approved sevabertinib, the first cancer drug developed based on research from Broad Institute scientists. Created by Bayer Healthcare Pharmaceuticals, this oral medication is intended for adult patients with specific HER2 mutations in non-small-cell lung cancer, typically after prior chemotherapy or immunotherapy. It offers a home-based treatment option for approximately 4,000 to 8,000 eligible lung cancer patients annually in the US, predominantly affecting women, including younger non-smokers.
- In October 2025, Roche’s Tecentriq (atezolizumab) has received FDA approval in combination with lurbinectedin (Zepzelca) for first-line maintenance therapy of extensive-stage small cell lung cancer (ES-SCLC) in adults without disease progression after initial therapy. This marks the first approved combination therapy for ES-SCLC. The pivotal phase III IMforte study showed the combination therapy reduced the risk of disease progression or death by 46% and the risk of death by 27%, with a median overall survival of 13.2 months versus 10.6 months for Tecentriq alone, and a median progression-free survival of 5.4 months versus 2.1 months. The regimen is now a preferred option in the NCCN Guidelines for maintenance treatment.
- In July 2025, the FDA granted accelerated approval for sunvozertinib (Zegfrovy) to treat adults with metastatic non-small cell lung cancer (NSCLC) featuring EGFR exon 20 insertion mutations, after progression following platinum-based chemotherapy. The Oncomine Dx Express Test has been approved as a companion diagnostic to identify eligible patients. Efficacy was demonstrated in the WU-KONG1B trial, showing a 46% overall response rate and an average duration of response of 11.1 months in 85 subjects receiving 200 mg daily until disease progression or intolerable toxicity. Prescribing guidelines include warnings for interstitial lung disease, gastrointestinal and dermatologic reactions, ocular toxicity, and embryo-fetal toxicity.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- By Type
- By Therapy
- By Diagnosis
- By End-User Industry
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape - AstraZeneca PLC, Bristol-Myers Squibb, Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co., Inc., among others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Non-Small Cell Lung Cancer Market Report Segment
By Type
- Adenocarcinomas
- Squamous Cell Carcinoma
- Large Cell Carcinomas
- Others
By Therapy
- Chemotherapy
- Targeted Therapy
- Radiation Therapy
- Surgery
- Cryosurgery
- Others
By Diagnosis
- CT Scan
- X-Rays
- Sputum Cytology
- Bronchoscopy
- Laboratory Tests
- Thoracoscopy
- Others
By End-User Industry
- Multispeciality Hospitals
- Cancer Research Centers
Global Non-Small Cell Lung Cancer Market Report Segment by Region
North America
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/non-small-cell-lung-cancer-market